Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;68(9):e29123.
doi: 10.1002/pbc.29123. Epub 2021 Jun 1.

Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia

Stephanie J Si Lim  1   2   3   4 , Stephen A Grupp  1   2 , Amanda M DiNofia  1   2
Affiliations
Review

Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia

Stephanie J Si Lim et al. Pediatr Blood Cancer. 2021 Sep.

Abstract

The treatment landscape for cancer therapy has changed drastically over the past decade. Tisagenlecleucel, the first genetically engineered adoptive cellular therapy approved by the United States Food and Drug Administration, has revolutionized this field by demonstrating impressive clinical success in children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Now 3 years since its approval, we have gained a deeper understanding on the basic immunobiology and clinical efficacy of this drug. This review will provide an updated summary of tisagenlecleucel in childhood and young adults with r/r B-ALL, common side effects and their associated management strategies, as well as barriers that remain to be addressed in order to realize the maximum potential of this drug.

Keywords: immunotherapy; leukemia; oncology; pediatric; tisagenlecleucel.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

REFERENCES

    1. Nguyen K, Devidas M, Cheng SC, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008;22(12):2142-2150.
    1. FDA. FDA Approves Tisagenlecleucel for B-cell ALL and Tocilizumab for Cytokine Release Syndrome. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro.... Accessed September 26, 2020.
    1. Novartis. Kymriah (Tisagenlecleucel), the First-in-Class CAR-T Therapy from Novartis, Receives Second FDA Approval to Treat Appropriate r/r Patients with Large B-Cell Lymphoma. https://www.novartis.com/news/media-releases/kymriah-tisagenlecleucel-fi.... Accessed July 18, 2020.
    1. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83-103.
    1. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541-1552.

MeSH terms

Substances

LinkOut - more resources